ChromaDex Corp (NASDAQ:CDXC) has announced the publication of results of the “Combined metabolic cofactor supplementation accelerates recovery in mild-to-moderate COVID-19″ study on the medRxiv.org.
COVID-19 patients in the study showed a 29% reduction in recovery time
The second phase study reported that patients with mild-to-moderate coronavirus experienced a reduction of 29% in recovery time. The reduction in recovery period was for those that received standard care and a nutritional protocol that included nicotinamide riboside (NR). Addition nutritional support was meant to encourage healthy mitochondria function and also reduced the recovery time to 6.6 days compared to the average placebo recovery period of 9.3 days
COVID-19 has been linked with metabolic conditions like obesity, high blood sugar, hypertension, low HDL cholesterol, and high triglycerides. This puts individuals with these conditions at a higher risk for debilitating outcomes. There was significant liver function improvement for patients that received a nutritional protocol that consisted of L-serine, Nicotinamide riboside (NR), L-carnitine tartrate, and N-acetyl-L-cysteine (NAC).
Rob Fried, the CEO of ChromaDex, said that the study conducted on almost 100 participants resulted in the accelerated recovery period for patients with COVID-19, and it builds on existing research. Currently, there are 11 published human clinical trials showing efficacy and safety of NTR in various indications. Fried added that there are also other studies in the work that include those mainly focusing on COVID-19.
Study conducted in collaboration with ScandiBio Therapeutics
This research was carried in collaboration with ScandiBio Therapeutics, a Swedish biotech company originating from the Science for Life Laboratory infrastructures. Dr. Adil Mardinoglu was the lead researcher for the study, which took place in Turkey at the Umraniye teaching and Research Hospital, University of Health Sciences. ChromaDex supplied NR for the study through the ChromaDex External Research Program.
The open-label, placebo-controlled, randomized phase 2 study evaluated 100 outpatients with COVID-19. They were randomized in 3:1 to receive hydroxychloroquine as a standard of care in combination with national protocol or placebo twice daily starting after around 24-48 hours of diagnosis. The subjects received standard of care for five days and then either nutritional protocol or placebo for two weeks.